BDTX (Black Diamond Therapeutics) Institutional Ownership: 71.06% (As of Jul. 21, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BDTX Black Diamond Therapeutics Inc BDTX
35 GF Score
Price $1.81
! 2 Warning Signs
View Full Analysis

What is Black Diamond Therapeutics Institutional Ownership?

Black Diamond Therapeutics BDTX +1.12% 35 Institutional Ownership is 71.06% as of Jul. 21, 2026. GuruFocus rates BDTX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review.

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Black Diamond Therapeutics's institutional ownership is 71.06%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Black Diamond Therapeutics's Insider Ownership is 2.89%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Black Diamond Therapeutics's Float Percentage Of Total Shares Outstanding is 69.50%.

Black Diamond Therapeutics Institutional Ownership Historical Data

* Premium members only.

The historical data trend for Black Diamond Therapeutics's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Black Diamond Therapeutics Institutional Ownership Chart

Black Diamond Therapeutics Historical Data

The historical data trend for Black Diamond Therapeutics can be seen below:

2025-09-30 2025-10-31 2025-11-30 2025-12-31 2026-01-31 2026-02-28 2026-03-31 2026-04-30 2026-05-31 2026-06-30
Institutional Ownership 31.99 31.93 34.76 36.12 36.62 37.47 38.59 38.35 37.52 41.18
BDTX
35GF Score
Black Diamond Therapeutics Inc BDTX
Institutional Ownership is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Black Diamond Therapeutics Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

What does a Institutional Ownership of 71.06% mean?
Black Diamond Therapeutics (BDTX) has a Institutional Ownership of 71.06% as of Jul. 21, 2026. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Black Diamond Therapeutics and its competitors.
Is Black Diamond Therapeutics' Institutional Ownership too high?
Black Diamond Therapeutics' current Institutional Ownership is 71.06%. Overall, Black Diamond Therapeutics has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Black Diamond Therapeutics' Institutional Ownership compare to CGTX and PMN?
Black Diamond Therapeutics' Institutional Ownership of 71.06% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Institutional Ownership for a Biotechnology company?
A good Institutional Ownership depends on the Biotechnology industry context. However, Institutional Ownership should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Institutional Ownership mean?
A high Institutional Ownership can signal that a stock is expensive relative to its fundamentals. Institutional ownership equals the percent of shares owned by financial institutions relative to total shares. View historical data on Black Diamond Therapeutics and its competitors. Black Diamond Therapeutics's current Institutional Ownership is 71.06%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Black Diamond Therapeutics stock overvalued right now?
Black Diamond Therapeutics (BDTX) has a current Institutional Ownership of 71.06%. The current Institutional Ownership is 71.06%. Black Diamond Therapeutics' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Institutional Ownership calculated?
Institutional Ownership is calculated from a company's financial statements. For Black Diamond Therapeutics (BDTX), the current Institutional Ownership is 71.06% as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Black Diamond Therapeutics Business Description

Address 245 First Street, 18th Floor, Cambridge, MA, USA, 02142
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.
35GF Score

Get the complete analysis for BDTX

Institutional Ownership is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.81
Price